Eli Lilly posts long-term data for eczema therapy Ebglyss
by
Contributor since / Followers
Contributor since / Followers
2 weeks ago
jetcityimage/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) on Friday said that its recently approved eczema therapy Ebglyss led to complete skin clearance in 50% of individuals who took part in a long-term extension study.
Citing data from ADjoin, a long-term extension study of the company’s